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R egional M etastasis in  Head and N eck  
Squam ous C<fll Carcinoma: R evised  
Value o f US w ith US-guided FNAB1
PURPOSE: To verify the acclaimed 
accuracy of ultrasound (US) combined 
with US-guided fine-needle aspiration 
biopsy (FNAB) in the detection of 
lymph node metastasis in the neck and 
to evaluate the interobserver variability.
MATERIALS AND METHODS: In a 
prospective, multicenter study of 185 
patients with head and neck squamous 
cell carcinoma, US (n = 238 neck sides) 
with US-guided FNAB (n = 178 neck 
sides) was used for evaluation of the 
lymph node status of the neck. Findings 
were correlated with those of histo­
pathologic examination in 238 neck 
sides.
RESULTS: US with US-guided FNAB 
had a sensitivity of 77% and a speci­
ficity of 100%. Nineteen of 178 aspira­
tions were nondiagnostic. There were 
no significant differences between 
the four participating hospitals or the 
individual sonologists (P > .05).
CONCLUSION: Sensitivity of US 
with US-guided FNAB was slightly 
lower compared with previous re­
ports. Specificity was similar to pre­
vious reports. Interobserver variabil­
ity appeared to be low. The validity 
of US with US-guided FNAB is high 
and warrants widespread use of the 
procedure for evaluation of the neck.
Index terms: Biopsies, technology, 28.1261 • 
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Th e  status of the lymph nodes in the neck is crucial to the treat­
ment and prognosis of patients w ith 
head and neck squamous cell carci­
noma (SCC). The prognosis is mainly 
determined on the basis of nodal dis­
ease: The presence of a single cervical 
lymph node metastasis in the ipsilat- 
eral side of the neck decreases the ex­
pected survival by approximately 50%. 
A contralateral affected node also re­
duces the expected survival by half (1).
In general, a patient with head and 
neck SCC and regional metastasis will 
be treated with irradiation of the 
neck, surgery, or both, Even w hen no 
nodes are detected, most head and 
neck oncologists will treat the neck 
electively w hen (clinically undetec­
ted) regional metastasis is likely. In 
most hospitals, elective neck treat­
ment will be performed if the fre­
quency of occult metastasis is more 
than 15%, In clinical practice, this 
means that patients with oral, oro­
pharyngeal, hypopharyngeal, or su­
pra- and subglottic laryngeal carcino­
mas will be treated electively for the 
lymph nodes of the neck (2), If the 
probability of regional metastasis is 
reduced, the number of elective treat­
ments will be decreased (2).
Until recently, accurate assessment 
of the neck of patients with head and 
neck SCC was not possible. Palpation 
and lymphangiography are not reli­
able (3-5). Magnetic resonance (MR) 
imaging and computed tomography 
(CT) are useful (6- 10); however, these 
are expensive and not always avail­
able. In addition, differentiation be­
tween nodes with and those without 
métastasés on the basis of radiologic 
characteristics only has a relatively 
low specificity (4,9,11-17). Immuno­
logic assays may prove to be useful in 
the future bu t are still under investi­
gation (18), Ultrasound (US) of the 
neck combined with US-guided fine- 
needle aspiration biopsy (FNAB) was 
dem onstrated to be very accurate in 
the evaluation of regional metastatic 
disease (13,19,20). This technique 
combines the high sensitivity of US 
with the excellent specificity of FNAB 
(21-24). A sensitivity of 98% and a speci­
ficity of 95% have been reported (20).
In view of the test characteristics of 
US with US-guided FNAB, this diag­
nostic procedure may have a substan­
tial impact on clinical management of 
patients with head and neck SCC (2). 
O pponents have suggested, however, 
that the results of both US and US- 
guided FNAB are very much deter­
mined by the expertise of those who 
perform the investigation. Therefore, 
a prospective, multicenter study on 
the value of US with US-guided 
FNAB was undertaken.
The object of our study was to 
verify the acclaimed accuracy of US 
with US-guided FNAB in the diagno­
sis of metastatic neck disease in pa­
tients with head and neck SCC. A 
second objective was to investigate 
w hether major differences in the ac­
curacy of the combined procedure 
occur w hen the tests are performed 
by different investigators. Further­
more, we studied other factors that 
could possibly influence the results of 
US with US-guided FNAB (eg, pri­
mary tumor site and node level).
MATERIALS A N D  METHODS
The multicenter study was performed at 
four hospitals in The Netherlands by 39
Abbreviations: FNAB = fine-needle aspiration 
biopsy, SCC = squamous cell carcinoma.
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sonologists between March 1992 and Sep­
tember 1993. All patients with head and 
neck SCC (nonirradiated or irradiated) 
who underwent neck dissection(s) as part 
of their treatment were eligible for this 
study.
The neck of each patient was examined 
by an experienced head and neck oncolo­
gist (P.K, J.J.M., C.A.M., H.A.M.M., H.A.A.S., 
M.F.d.B., R.J.B.dJ,). The findings were re­
corded, together with other relevant clini­
cal information. At this stage, cytologic 
examination was not performed. Subse­
quently, the neck was examined by one of 
the sonologists (J.A.v.O., J.S.L., R.H.K., 
F.B.M.J.). All clinical information was pro­
vided. The findings of the sonologist(s) 
were recorded on a worksheet. Subse­
quently, US-guided FNAB of nodes that 
were depicted with US was performed in 
178 cases. In case of multiplicity, US- 
guided FNAB was performed of the larg­
est node, nodes showing central hypo- 
echogeneity, or the most cranial and 
caudal nodes in the areas at highest risk 
for metastasis. The US examinations and 
the US-guided FNABs were performed 
with the following scanners: a model 620/ 
650CL (Aloka, Tokyo, Japan), with a 7.5- 
MHz linear-array probe; a model SSA 
250A (Toshiba Europe, Zoetermeer, The 
Netherlands), with a 7.5-MHz mechanical 
sector type of probe with a built-in water 
path; and a model 128 XP (Acuson, Moun­
tain View, Calif), with a 7-MHz linear-ar­
ray probe. The procedure was performed 
as described previously (20,25) (Figure). 
Cytologic examination was performed by 
experienced cytopathologists, Nondiag­
nostic aspirations had to be repeated. Be­
cause the trauma associated with rigid en­
doscopy may cause an increase in the 
number and size of lymph nodes, both 
palpation and US were preferably per­
formed before endoscopy.
Neck dissection had to be performed 
within 3 weeks. The specimen was labeled 
by the surgeon as level I-V, according to 
the Memorial Sloan-Kettering classifica­
tion (26). Subsequently, histologic exami­
nation of the neck dissection specimen 
was performed according to a standard­
ized protocol, and the findings of the pa­
thologist (J.H.J.M.v.K., F.T.B., S.C.H.L., 
J.M.W.v.T.) were recorded per level. The 
results of palpation and US with US- 
guided FNAB were compared with the 
results of the histopathologic examination. 
We considered the results per neck side 
since the treatment of metastatic disease is 
for a neck rather than for a single node: 
The detection of a single metastasis results 
in the treatment of the whole neck side. 
Moreover, it is practically impossible to 
match an aspirated or palpable node with 
the same node in the neck dissection 
specimen.
The test result of US with US-guided 
FNAB in fact consisted of the combined 
results of two separate tests: US and US- 
guided FNAB (Table 1). US may be scored 
positive (lymph nodes depicted) or nega­
tive (no lymph nodes visualized), No mor­
phologic criteria were used. Merely the 
depiction of lymph nodes, therefore, was
used for scoring the result of US. US- 
guided FNAB may be (a) not performed, 
(fa) negative (reactive), (c) positive (meta­
static), or (d) nondiagnostic. Therefore, 
five combinations of test results were dis­
tinguished. The cases with nondiagnostic 
aspirates (not repeated or repeatedly non­
diagnostic) were excluded. Therefore, US 
with US-guided FNAB was considered 
negative if (a) no nodes could be visual­
ized, (b) nodes were too small to aspirate 
(< 5 mm), or (c) nodes appeared to be re­
active at cytologic examination. The test 
was considered positive if the aspirate 
contained tumor cells.
The reference standard (histopathologic 
examination) was considered negative 
when no evidence of metastases was 
found in neck dissection specimens and 
positive when one or more metastases 
were diagnosed.
Since the main objective of this study 
was to establish the value of US with US- 
guided FNAB in the discrimination be­
tween neck sides with or without metastatic 
disease, the result of US-guided FNAB of 
one or more nodes was considered to be 
representative for the neck as a whole. In 
other words, when US-guided FNAB for 
example showed a reactive node that was 
confirmed with histopathologic examina­
tion but a metastasis was found in another 
lymph node that was not depicted at US, 
the test result was considered false-nega­
tive.
Differences in test characteristics such as 
sensitivity and specificity were evaluated 
by using the x2 test. Differences were con­
sidered statistically significant at P < ,05.
RESULTS
A total of 185 patients (133 men, 52 
women; age range, 25-85 years; mean 
age, 59 years) participated in this 
study, Of these, 132 patients under­
went unilateral and 53 patients un­
derwent bilateral neck dissection, re­
sulting in the inclusion of 238 neck 
sides. The primary tumor sites and 
tumor stages are listed in Table 2.
Palpation and US with US-guided 
FNAB
The results of US with US-guided 
FNAB are shown in Table 1. With pal­
pation, a sensitivity of 66% and a 
specificity of 92% were achieved 
(Table 3). For US with US-guided 
FNAB, a sensitivity of 77% and a 
specificity of 100% were found (Table 
3). Some nodes detected with palpa­
tion were not detected by using US 
with US-guided FNAB. Therefore, the 
results of palpation and US with US- 
guided FNAB are supplementary. 
When, as is done in clinical practice, 
the results of US with US-guided 
FNAB and palpation were combined, 
the sensitivity was 80% with a speci­
ficity of 92%.
Lymph node metastasis. US image obtained 
during US-guided FNAB. Tip of the needle is 
depicted as a hyperechoic spot (arrow). For 
this image, a 10-MHz sector-type probe with 
a built-in water path was used to obtain an 
optimal graphical representation.
A considerable proportion of the 
aspirates (19 of 178 cases) were nondi­
agnostic, and FNAB was not repeated. 
In fact, in most cases of initially non­
diagnostic aspirates, FNAB was not 
repeated. Histologic examination of 
the neck dissection specimens re­
vealed that 12 of these specimens in 
fact contained metastases and seven 
had reactive nodes, This might sug­
gest that a nondiagnostic aspirate is 
more likely to be from a metastatic 
node. However, the proportion of 
metastatic nodes (12 of 19 nodes) re­
flects the prevalence of lymph node 
metastases in the entire population 
(155 of 238 cases). For the present 
study, the nondiagnostic aspirates 
were excluded.
Sonologists and Hospitals
To evaluate the interobserver variabil­
ity, we compared the results of six son­
ologists who examined at least 13 neck 
sides (varying from 13 to 53 neck sides) 
and the combined results of a group of 
33 sonologists (78 neck sides) who per­
formed the examination less frequently. 
No statistically significant differences 
were found between the characteristics 
of these (groups of) sonologists (Table 3) 
or between the participating hospitals 
(data not shown, P = .14).
Primary Tumor Sites 
and N eck Levels
The results of US with US-guided 
FNAB for different primary tumor 
sites are summarized in Table 3, Al­
though there seem to be marked dif­
ferences, note that the number of 
cases in some of the groups is fairly 
small. There were no statistically sig­
nificant differences in sensitivity for 
the different primary sites (P = .51),
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Histologie Result
V/■, US v  US-guided FNAB Negative Positive /  Total
Negative Not performed
Positive Not performed 9 /
Positive Negative 49 /
Positive Nondiagnostic 12
' Positive Positive ; : 0 110 110
-Total /  '• vT-v:;
....................................................................................................... 
1
C
O
-OO 238i '
B: Combined Procedure* * ' ' * * . : • • ! : • * . : V
Histologic Result ••• * : • ! *• *.*.*•' * • •
US with US-guided FNAB Negative Positive Total
Negative 76 33 109
Positive 0 D O 110
Total% ............  ► * , | « « « « , : V
i
o
v 143 /: 219
4 The 19 nondiagnostic aspirates were excluded from this analysis.
Table 2
Primary Tumor Site and Stage of 
Tumor according to the TNM 
Classification
Variable
No. of 
Patients
Site
Larynx 60
Hypopharynx 15
Oropharynx 26
Floor of mouth 22
Oral tongue 36
Oral cavity (other) 15
Other sites 7
Unknown primary 
Stage
4
T1 ' 20
T2 40
42
48
Unknown primary v-Y  . 4 ='■:
Recurrence 25
Unknown 6
To evaluate differences in detecting 
métastasés in lymph nodes of the dif­
ferent neck levels (I-V), we investi­
gated whether métastasés were missed 
more often in particular regions. The 
number of lymph node métastasés per 
level was listed, and the fraction of mé­
tastasés not detected by using US with 
US-guided FNAB was calculated. No 
statistically significant differences were 
found between the various levels (P = 
.52) (Table 4).
DISCUSSION
To assess the status of lymph nodes 
in the neck in patients with head and 
neck SCC, various (imaging) tech­
niques have been explored. CT and 
MR imaging allow detection of small 
structures, such as lymph nodes, with 
high sensitivity. Although several ra­
diologic characteristics of metastatic 
nodes have been defined (size, shape, 
central necrosis, obliteration of fascial 
planes, contiguous nodes), several 
authors have criticized these criteria 
(4,12,15-17,27-29). In our opinion, 
differentiation between benign and 
metastatic nodes only on the basis of 
radiologic characteristics remains dif­
ficult and unreliable.
US is characterized by a superior 
sensitivity rate for detection of lymph 
nodes (3,30). The detection of more 
lymph nodes, however, inevitably 
leads to a lower specificity; A consid­
erable proportion of the lymph nodes 
detected with US will be benign. As 
with CT and MR imaging, differentia­
tion between reactive and metastatic 
nodes is based on morphologic crite­
ria (13,28,31). This leads to a relatively 
low specificity, although some au­
thors reported high specificity rates 
up to 91% with US alone (30).
With the introduction of the con­
cept of US-guided FNAB (19,20), the 
high sensitivity of US is combined 
with the high specificity of cytologic 
examination (20). Sensitivity and 
specificity have been reported as high 
as 98% and 95%, respectively. In a 
subsequent similar study, other au­
thors reported an even higher speci­
ficity of 100% but at the expense of a 
lower sensitivity of 90% (13). Critics, 
however, doubted that these rates 
could be reproduced if the technique 
was performed by different sonolo­
gists in "daily practice/ 7
In our study, only patients under­
going neck dissection as part of their 
treatment were included because his­
tologic examination was used as the 
standard of reference. Although this 
introduces an inevitable bias by in­
creasing the number of cases with 
metastatic disease, all reports of stud­
ies of US with US-guided FNAB, CT, 
or MR imaging are subject to this limi­
tation.
The accuracy and sensitivity of US 
with US-guided FNAB in our study 
were not as high as found in previous 
studies. The specificity, however, was 
comparable. Compared with other diag­
nostic imaging techniques, the sensitiv­
ity of US with US-guided FNAB found 
in our study is in the range of that re­
ported for CT (4,6,9,12,13,15,16) and MR 
imaging (5,9). The high specificity of up  
to 100% found in the present and previ­
ous studies (13,20) compares favorably 
with that of CT and MR imaging.
Most studies concerning CT found a 
specificity of no more than 70%-85% 
(4,9,12,13,15,16). A few studies found 
higher specificity rates (up to 94%) by 
using morphologic criteria (28).
In most studies concerning the value 
of CT and MR imaging for assessment of 
the neck, morphologic and/or size crite­
ria are used. By choosing an optimal 
cutoff point, false-positive and false- 
negative results will be introduced. As a 
consequence, in these studies, a higher 
sensitivity results in a lower specificity 
and vice versa. For example, Stevens et 
al (12), Close et al (15), Hillsamer et al (9), 
and Friedman et al (11) found sensitivity 
rates of 97%, 86.5%, 84%, and 95% 
paired to a much lower specificity of 
82%, 71%, 71%, and 77%, respectively.
In contrast, Feinmesser et al (4) found a 
relatively low sensitivity of 60% with a 
higher specificity of 85%. Although US 
alone suffers from the same phenom­
enon, US with US-guided FNAB does 
not because US determines the sensitiv­
ity and US-guided FNAB the specificity.
Another factor influencing the re ­
sults of these studies is the frequency 
of metastasis. Studies with a high 
number of patients having metastasis 
or advanced-stage disease will show 
higher sensitivity rates for the studied 
diagnostic techniques. For example, in 
studies with a relatively high number 
of cases with clinically or histologi­
cally positive nodes, higher sensitivity 
rates for CT were obtained, up  to 91 % 
(6,12,15), whereas in studies with more 
cases with negative nodes, sensitivity 
rates for CT were lower (eg, 60%) (4). 
The only study, to our knowledge, in 
which the results of US with US-guided 
FNAB, CT, and MR imaging were com­
pared in the same study population
Volume 198 • Number 3 Radiology • 821
Diagnostic Indexes
Variable
No, of 
Neck 
Sides
Frequency
(%)
Sensitivity
Positive Négative : 
Specificity Predictive Predictive Accuracy
p
alpation and US with US-guided FNAB
Palpation 238 65 92
US with US- . • .. « . • • V  , ;
guided.FNAB
TTQ wifK77«?-
219 - : 77 100
\JD Yv 1UV Ww-
guided FNAB
•
• * • . * ’*• ; * • • * * .• * \ ' •• . ' ! ' : : • * •’ /.■ '
plus palpation 219 65 80 92 100 87
' *• • * . * * * * . .  * * • : ** * . Breakdown per Sonologist
A ■ 13 85 82 100 100 50
B 13 71 90 100 100 75 92
C 15 60 67 100 100 67 80
D 48 58 68 100 100 69 81
B 20 60 75 100 100 73 85
F 37 54 80 100 100 81 89
Others 73 73 79 100 100 65 85
Breakdown per Primary Tumor Site
*
Larynx 71 t y r j 84 100 100 64 86
Hypopharynx 15 70 83 100 100 60 87
Oropharynx 28 93 73 100 100 22 82
Floor of mouth 38 37 57 100 100 80 84
Oral tongue 38 39 73 100 100 85 89
Oral cavity (other) 16 63 70 100 100 67 81
Oral cavity (total) 92 42 67 100 100 80 86
showed superior results of US wi th US- 
guided FNAB (13).
Another advantage of US with US- 
guided FNAB over CT and MR imag­
ing is the lower cost (in the Nether­
lands, the costs of CT are about four 
times as high as those of US with US- 
guided FNAB). Moreover, for US with 
US-guided FNAB, patients do not 
have to lie dow n (for a prolonged pe­
riod of time), which is more conve­
nient in these predominantly elderly 
and/or dyspneic patients. Contrary to 
CT and especially MR imaging, US 
will not be problematic in patients 
inclined to be claustrophobic. Finally, 
in our opinion, FNAB is hardly a more 
invasive or risky procedure than the 
administration of intravenous contrast 
material in CT or MR imaging.
Unfortunately, in 19 cases of nondi­
agnostic aspirates, FNAB was not re­
peated. Repeating these aspirations, 
as was requested according to the 
protocol, would definitely have im­
proved the test results. We cannot, 
Ziowever, prove this with our material 
because for most cases of nondiagnos­
tic aspirates, FNAB was not repeated. 
The rate of nondiagnostic US-guided 
FNABs (19 [11%] of 178 aspirates) is in 
the range found in previous studies 
(1%-15%) (20,32,33).
Our data show that the results of 
US with US-guided FNAB are not as 
investigator dependent as often sug­
gested. No major differences were 
found between experienced and less 
experienced sonologists.
Although the differences were not 
statistically significant, it appeared 
that the accuracy of US with US- 
guided FNAB was determined by the 
site of the primary tumor. There are 
two explanations for this finding.
First, this may be due to a difference 
in frequency (Table 3). This influ­
ences, in particular, the negative and 
positive predictive values. Second, 
different primary tumors metastasize 
to different neck levels, and lymph 
node metastases in some levels are 
more difficult to detect by using US 
with US-guided FNAB than others. 
This phenomenon has been described 
in earlier studies (34,35), In our study, 
it seemed more difficult to detect 
lymph node metastases in levels I and 
V than in levels II, III and IV, although 
the differences were not statistically sig­
nificant. Therefore, the favorable sensi­
tivity rates for laryngeal and pharyngeal 
carcinoma when compared with floor of 
mouth or oropharyngeal carcinoma may 
be because the former metastasize less 
frequently to level I.
The difficulty in the detection of 
nodes in level I by using US with US-
guided FNAB may be caused by the 
mandible. However, nodes missed 
with US at this level may be detected 
with palpation: With bimanual pal­
pation, examination of level I is rela­
tively easy to perform. If the results of 
palpation are added to the results of 
US with US-guided FNAB in cancer of 
the floor of mouth, a primary tumor 
predominantly metastasizing to level 
I, sensitivity improves from 57% to 
79% at the expense of a specificity 
declining from 100% to 83%. It seems 
justified, therefore, to use the combi­
nation of the results of both methods 
of examination in clinical practice 
(Table 3).
In this prospective, multicenter 
study, the sensitivity ofU Sw ith  US- 
guided FNAB appeared to be slightly 
lower compared with that of previous 
studies but comparable with the sen­
sitivity of CT and MR imaging. The 
specificity of US with US-guided 
FNAB found in our study is similar to 
that of previous studies and  superior 
to the specificity of CT and MR imag­
ing. Repeating FNAB for nondiagnos­
tic aspirates may further improve the 
test characteristics of US with US- 
guided FNAB.
Palpation remains an important 
tool for assessment of the lymph 
nodes of the neck, A combination of 
palpation and US with US-guided 
FNAB improves the sensitivity of the 
diagnostic procedure. In addition, in
Table 4
Metastases pet Lymph Node Level 
Not Detected by Using US 
with US-guided FNAB
Lymph 
Node Level
No. of 
Metastases
Undetected
Metastases
I 44 10(23)
II 92 16.(17)
III 65 9 (14)
ÏV 31 3 (10)
V 12 3 (25)
Note.—Numbers in parentheses are percent' 
ages.
this study, the often suggested in­
terobserver variability of US and US- 
guided FNAB could no t be confirmed. 
The results of this study can be con­
sidered as a validation of and recom­
mendation for the use of US with US- 
guided FNAB for evaluation of the 
neck in patients with head and neck
SCC. ■
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